Startup diligence,
written by AI.
Each report runs end-to-end research on a private startup and writes it up like an investment committee memo: cover snapshot, executive summary, market sizing, competitors, financials, product, customers, risks, and valuation. Every claim links to a public source.
Latest reports
Newest generated reports first. Top-rated rankings live on their own page.
Veriff
A profitable, fast-growing identity-verification leader whose quality is high but whose price is unconfirmed against a three-year-stale $1.5B mark.
- Valuation
- $1.5B
- Revenue run-rate
- $110M
- ARR
- $110M
- Growth
- 83%
Noom
Noom is a real, large-scale consumer-health brand whose 2021 $3.7B mark is no longer credible — secondary markets already imply ~$720M — and whose investability now hinges on whether the GLP-1 Noom Med pivot can offset behavioral-app revenue decline and structural disruption.
- Valuation
- $3.7B
- Revenue run-rate
- $400M
Monolith Materials
A first-of-its-kind commercial plasma-pyrolysis producer with real technology and blue-chip backing, but thin public financials, single-plant scale, customer/loan concentration and a DOE loan under cancellation threat warrant deeper diligence before underwriting the $1B+ valuation.
- Valuation
- $1B
Incode Technologies
A fast-growing LATAM identity-verification leader with real scale and revenue, but a stretched reported valuation, concentration, and biometric regulatory exposure warrant close tracking before conviction.
- Valuation
- $1.3B
- Revenue run-rate
- $170M
- ARR
- $170M
- Growth
- 80%
Avoca
Avoca has genuine vertical AI traction and elite investor validation in an underpenetrated home-services market, but the $1 billion valuation on undisclosed eight-figure ARR creates too wide an uncertainty band to underwrite without data-room access — warranting a track posture until key unit economics are verified.
- Valuation
- $1B
Divert
Divert has assembled a defensible end-to-end food waste circular economy platform with genuine operational switching costs, but its $1B+ Series C valuation implies revenue well above two-facility run-rate reality and complete financial opacity precludes independent underwriting, warranting a track posture pending disclosure.
- Valuation
- $1B
Alloy Therapeutics
Alloy Therapeutics looks strategically relevant and partner-rich, but the current $1.0B mark already assumes durable economics that public disclosures do not yet substantiate.
- Valuation
- $1B
vVardis
vVardis has created a genuinely novel dental therapeutic category with rapid US institutional adoption and unicorn-level backing, but the complete absence of disclosed financials and persistent insurance reimbursement gaps support only a research-more stance until an S-1 filing provides the evidence needed to underwrite the $1B+ private-market valuation.
- Valuation
- $1B
Vi Labs
Vi Labs is a qualified BUY as a leading enterprise AI platform for healthcare data intelligence, supported by a $1.64B valuation, a 190M-record data moat, and 100+ enterprise customers, tempered by undisclosed financials.
- Valuation
- $1.6B
Talos
Talos is a strategically strong institutional digital asset infrastructure platform with credible product breadth and customer traction, but its current valuation already prices in substantial future execution while public disclosure remains too thin for high-conviction underwriting.
- Valuation
- $1.5B
- Revenue run-rate
- $45.5M
- Growth
- 67%
Advance Intelligence Group
Advance Intelligence Group is one of the most advanced SEA fintech multi-product platforms at profitability inflection, but undisclosed credit quality and an uncertain IPO path make this a conditional accumulate at or below the 2021 round valuation.
- Valuation
- $2B
- Revenue run-rate
- $500M
- Growth
- 50%
Octane
Octane is a profitable, high-growth specialty fintech lender with a defensible moat in powersports and recreational markets; the $1.3B valuation is fair given GAAP profitability and 29% originations growth, making this a buy for specialty fintech investors with medium confidence pending full financial disclosure.
- Valuation
- $1.3B
- Revenue run-rate
- $400M
- Growth
- 29%
Showing 12 of 672 reports.
See all 672 reports →